{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:20:44Z","timestamp":1792545644873,"version":"4.5.0"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2014,3,11]],"date-time":"2014-03-11T00:00:00Z","timestamp":1394496000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0090353","type":"journal-article","created":{"date-parts":[[2014,3,11]],"date-time":"2014-03-11T20:25:14Z","timestamp":1394569514000},"page":"e90353","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":428,"title":["Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGF\u03b2) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma"],"prefix":"10.1371","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct00356460","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"John C.","family":"Morris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette R.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Olencki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey I.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce J.","family":"Dezube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Reiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay A.","family":"Berzofsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald P.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,3,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1073\/pnas.78.9.5339","article-title":"New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues","volume":"78","author":"AB Roberts","year":"1981","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2008.07.001","article-title":"TGFbeta in Cancer","volume":"134","author":"J Massague","year":"2008","journal-title":"Cell"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1158\/1078-0432.CCR-07-1157","article-title":"Transforming growth factor-beta and the immune response: implications for anticancer therapy","volume":"13","author":"SH Wrzesinski","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10549-008-0184-1","article-title":"Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer?","volume":"115","author":"AR Tan","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.gde.2010.12.004","article-title":"Switching TGFbeta from a tumor suppressor to a tumor promoter","volume":"21","author":"GJ Inman","year":"2011","journal-title":"Curr Opin Genet Dev"},{"key":"ref6","first-page":"1027","article-title":"Chronic exposure of cultured transformed mouse epidermal cells to transforming growth factor-beta 1 induces an epithelial-mesenchymal transdifferentiation and a spindle tumoral phenotype","volume":"6","author":"C Caulin","year":"1995","journal-title":"Cell Growth Differ"},{"key":"ref7","first-page":"4222","article-title":"Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation","volume":"61","author":"V Ellenrieder","year":"2001","journal-title":"Cancer Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e27090","DOI":"10.1371\/journal.pone.0027090","article-title":"Anti-transforming growth factor ss antibody treatment rescues bone loss and prevents breast cancer metastasis to bone","volume":"6","author":"S Biswas","year":"2011","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"24571","DOI":"10.1074\/jbc.M202561200","article-title":"Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways","volume":"277","author":"SM Kakonen","year":"2002","journal-title":"J Biol Chem"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1158\/1078-0432.CCR-10-2429","article-title":"TGF-beta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models","volume":"17","author":"S Liao","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref11","first-page":"1860","article-title":"Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines","volume":"63","author":"JJ Kobie","year":"2003","journal-title":"Cancer Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.coi.2004.01.010","article-title":"Immunoregulatory T cells in tumor immunity","volume":"16","author":"M Terabe","year":"2004","journal-title":"Curr Opin Immunol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1023\/A:1022951824806","article-title":"Reversal of tumor-induced immunosuppression by TGF-beta inhibitors","volume":"21","author":"S Wojtowicz-Praga","year":"2003","journal-title":"Invest New Drugs"},{"key":"ref14","first-page":"575","article-title":"Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells","volume":"54","author":"U Rodeck","year":"1994","journal-title":"Cancer Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/(SICI)1097-0045(19980915)37:1<19::AID-PROS4>3.0.CO;2-3","article-title":"Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer","volume":"37","author":"P Wikstrom","year":"1998","journal-title":"Prostate"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000030255","article-title":"Increased transforming growth factor beta1 plasma level in patients with renal cell carcinoma: a tumor-specific marker?","volume":"60","author":"H Wunderlich","year":"1998","journal-title":"Urol Int"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cca.2006.02.027","article-title":"Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients","volume":"371","author":"V Ivanovic","year":"2006","journal-title":"Clin Chim Acta"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1172\/JCI116871","article-title":"Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell\/host TGF-beta interactions in human breast cancer progression","volume":"92","author":"CL Arteaga","year":"1993","journal-title":"J Clin Invest"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.1158\/1078-0432.CCR-09-1067","article-title":"Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines","volume":"15","author":"R Ueda","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1158\/0008-5472.CAN-08-0215","article-title":"An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments","volume":"68","author":"JS Nam","year":"2008","journal-title":"Cancer Res"},{"key":"ref21","article-title":"Inhibition of TGF-\u03b2 and CXCR4 Signaling Promotes Cell Cycle Arrest and Apoptosis In Leukemic Cells Co-Cultured with Stromal Cells; 2010 December 4, 2010; Orlando, FL","author":"Y Zhou","year":"2010","journal-title":"American Society of Hematology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"6560","DOI":"10.1158\/1078-0432.CCR-09-1066","article-title":"Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody","volume":"15","author":"M Terabe","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1084\/jem.20022227","article-title":"Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence","volume":"198","author":"M Terabe","year":"2003","journal-title":"J Exp Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1476-4598-9-122","article-title":"Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis","volume":"9","author":"V Ganapathy","year":"2010","journal-title":"Mol Cancer"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Harper JW, Green T, Munroe K, Manning C, Tao J, <etal>et al<\/etal>.. (2010) Neutralization of TGF\u03b2 enhances the efficacy of chemotherapeutics in a preclinical model of triple negative breast cancer. American Association of Cancer Research Annual Meeting Washington, D.C.","DOI":"10.1158\/1538-7445.AM10-3826"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Munroe K, Manning C, Green T, Tao J, Simon K, <etal>et al<\/etal>.. (2009) Inhibition of metastases by a neutralizing TGFb-specific antibody involves the activity of cytotoxic T lymphocytes and natural killer cells. AACR-NCI-EORTC International Conference on Molecular Targets &amp; Cancer Therapeutics. Boston, MA.","DOI":"10.1158\/1535-7163.TARG-09-B244"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00002371-199605000-00001","article-title":"Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2","volume":"19","author":"S Wojtowicz-Praga","year":"1996","journal-title":"J Immunother Emphasis Tumor Immunol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"6754","DOI":"10.1158\/1078-0432.CCR-11-0544","article-title":"TGFbeta1 Inhibition Increases the Radiosensitivity of Breast Cancer Cells In Vitro and Promotes Tumor Control by Radiation In Vivo","volume":"17","author":"F Bouquet","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s002800050435","article-title":"Transforming growth factor-beta in in vivo resistance","volume":"37","author":"BA Teicher","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1172\/JCI30740","article-title":"Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression","volume":"117","author":"S Biswas","year":"2007","journal-title":"J Clin Invest"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/ki.2011.33","article-title":"A phase 1, single-dose study of fresolimumab, an anti-TGF-beta antibody, in treatment-resistant primary focal segmental glomerulosclerosis","volume":"79","author":"H Trachtman","year":"2011","journal-title":"Kidney Int"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"P Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"PB Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials","volume":"26","author":"EL Korn","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1365-4632.2007.03260.x","article-title":"Keratoacanthoma: a tumor in search of a classification","volume":"46","author":"A Karaa","year":"2007","journal-title":"Int J Dermatol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/modpathol.3800063","article-title":"Biological behavior of keratoacanthoma and squamous cell carcinoma: telomerase activity and COX-2 as potential markers","volume":"17","author":"TC Putti","year":"2004","journal-title":"Mod Pathol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/ng.780","article-title":"Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1","volume":"43","author":"DR Goudie","year":"2011","journal-title":"Nat Genet"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/j.jaad.2003.11.044","article-title":"Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab","volume":"50","author":"AC Esser","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1200\/JCO.2009.23.4823","article-title":"Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib","volume":"27","author":"JP Arnault","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":"RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors","volume":"366","author":"F Su","year":"2012","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/(SICI)1097-0215(19970328)71:1<49::AID-IJC10>3.0.CO;2-4","article-title":"Reversal of in vivo drug resistance by the transforming growth factor-beta inhibitor decorin","volume":"71","author":"BA Teicher","year":"1997","journal-title":"Int J Cancer"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"e62785","DOI":"10.1371\/journal.pone.0062785","article-title":"TGF-beta-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment","volume":"8","author":"Y Tabe","year":"2013","journal-title":"PLoS One"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"e10365","DOI":"10.1371\/journal.pone.0010365","article-title":"Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models","volume":"5","author":"A Bandyopadhyay","year":"2010","journal-title":"PLoS One"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1006\/excr.1998.4261","article-title":"Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy","volume":"245","author":"T Ohmori","year":"1998","journal-title":"Exp Cell Res"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1111\/j.1349-7006.2010.01646.x","article-title":"Enhanced antitumor efficacy of folate-linked liposomal doxorubicin with TGF-beta type I receptor inhibitor","volume":"101","author":"Y Taniguchi","year":"2010","journal-title":"Cancer Sci"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1073\/pnas.0611660104","article-title":"Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling","volume":"104","author":"MR Kano","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref47","unstructured":"Cheever AW, Matrisian LM, Weiner GJ, June CH, Finn O, <etal>et al<\/etal>.. (2009) Report of the immune response modifier pathway prioritization working group (IRMP WG). National Cancer Institute, NIH."},{"key":"ref48","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm0806-875","article-title":"Is cancer a disease of self-seeding?","volume":"12","author":"L Norton","year":"2006","journal-title":"Nat Med"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cell.2009.11.025","article-title":"Tumor self-seeding by circulating cancer cells","volume":"139","author":"MY Kim","year":"2009","journal-title":"Cell"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cell.2008.01.046","article-title":"TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4","volume":"133","author":"D Padua","year":"2008","journal-title":"Cell"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0090353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T04:10:36Z","timestamp":1588997436000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0090353"}},"subtitle":[],"editor":[{"given":"Jose Luis","family":"Perez-Gracia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,3,11]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,3,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0090353","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,11]]}}}